University of Iowa Hospitals and Clinics

Clinical Trial Details

Short Title
A Phase III Randomized Study of Chimeric Antibody 14.18 in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Official Title

A Phase III Randomized Study of Chimeric Antibody 14.18 in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue

Description

The standard treatment for neuroblastoma consists of chemotherapy, surgery, and radiation therapy. Children with high-risk neuroblastoma often respond to standard treatment at first, but there is a high risk that the cancer will come back. This study is being done to try to increase the number of children with high-risk neuroblastoma who can be cured.

Start Date
March 25, 2004
End Date
March 25, 2014
Gender Preference
None
Age Group
0 - 18 years
Principal Investigator
Ayman El-Sheikh, MD
Contact Info

Victoria Scaccia, 319-356-7875

Department
Department or Field of Study
Keywords
ANBL0032 ; cancer ; el-sheikh ; IRB#200401120 ; neuroblastoma ; pediatric ; phase 3 ; phase III ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.